SCHEMBL722765

SCHEMBL722765

Clc1ccnc2cc(I)oc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.34
SOS2 Q07890 1/20 0.34
CASP6 P55212 1/20 0.33
PSMB8 P28062 1/20 0.32
PSMB5 P28074 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
APP P05067 1/20 0.31
CYP1A2 P05177 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31
SLC6A2 P23975 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29767254 1.00 NR4A2 (0.34) NR4A2SOS2CASP6PSMB8PSMB5
SCHEMBL2211013 0.77 ALDH1A1 (0.35) NR4A2SOS2CASP6PSMB8PSMB5
SCHEMBL723857 0.76 NR4A2 (0.33) NR4A2SOS2CASP6PSMB8PSMB5
SCHEMBL30765207 0.76 NR4A2 (0.33) NR4A2SOS2CASP6PSMB8PSMB5
SCHEMBL4758600 0.73 NR4A2 (0.32) NR4A2SOS2CASP6
SCHEMBL1849392 0.73 RECQL (0.38) NR4A2SOS2CASP6KDM4EALDH1A1
SCHEMBL18340397 0.73 NR4A2 (0.32) NR4A2SOS2CASP6
SCHEMBL2207433 0.73 PSMB8 (0.42) NR4A2SOS2CASP6PSMB8PSMB5
SCHEMBL18348153 0.73 NR4A2 (0.35) NR4A2SOS2CASP6KDM4ETDP1
SCHEMBL2976981 0.72 ALDH1A1 (0.37) ALDH1A1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688778-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Biogen MA Inc. (US) 2026-02-11 EP disclosed
WO-2024211696-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES BIOGEN MA INC. (US) 2024-10-10 WO disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
WO-2024033280-A1 FUROPYRIDIN AND FUROPYRIMIDIN, INHIBITORS OF PI4K, FOR USE IN THE TREATMENT OF PARASITE INFECTION AND MALARIA MERCK PATENT GMBH (DE) 2024-02-15 WO disclosed
WO-2023021498-A1 FUSED AZOLE AND FURAN BASED NUCLEOSIDE ANALOGS AND USES THEREOF MOYA BIO LTD. (IL) 2023-02-23 WO disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 US disclosed
CN-114728980-A Pyrazole compound 江苏先声药业有限公司 2022-07-08 CN disclosed
WO-2021129621-A1 PYRAZOLE COMPOUNDS 江苏先声药业有限公司 2021-07-01 WO disclosed
WO-2021129621-A1 PYRAZOLE COMPOUNDS 江苏先声药业有限公司 2021-07-01 WO disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2012-05-17 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US disclosed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
EP-2137177-A2 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2009-12-30 EP disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069297-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 NR4A2 2825/4885SOS2 3189/4885CASP6 3121/4885
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 NR4A2 1278/4885SOS2 3713/4885CASP6 2262/4885
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 NR4A2 2825/4885SOS2 3189/4885CASP6 3121/4885
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 NR4A2 2825/4885SOS2 3189/4885CASP6 3121/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 NR4A2 1278/4885SOS2 3713/4885CASP6 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.